House Committee Approves Historic Medical Cannabis Research Bill
May 14th, 2018
There is no doubt that public support for cannabis legalization has been gaining momentum. According to Gallup, support for legalization has risen from less than 50 percent prior to 2010 to more than 64 percent by early 2018. The rise of Republican support to more than 50 percent in 2017 marked a key turning point since bipartisan bills could gain support.
Hundreds of cannabis reform bills have been filed in Congress over the years, but not a single one has ever been put to a vote – until now.
A House committee approved cannabis law reform legislation last Tuesday for the first time in history without attaching the measure to any larger bill. With broad bipartisan support, the bill signals that Congress could be ready to tackle real cannabis reforms.
The new bill, filed by Veterans’ Affairs Chairman Phil Roe (R-TN) and Tim Walz (D-MN) along with more than 50 cosponsors, would encourage the U.S. Department of Veteran Affairs to conduct research on cannabis’ medical benefits. Senators Jon Tester (D-MT) and Dan Sullivan (R-AK) introduced a companion bill in the Senate on Monday, as well.
What in the Bill?
While, Veterans’ Affairs is already allowed to participate in cannabis research, the new bill would strongly encourage reluctant leadership to research whole plant marijuana and extracts involving at least three different strains of cannabis with significant variants in phenotypic traits and various ratios of tetrahydrocannabinol and cannabidiol in chemical composition.
The research would be focused on examining varying methods of cannabis delivery, including topical applications, combustible, and noncombustible inhalation, and ingestion. While smoking cannabis has been the most popular consumption method, new forms of cannabis delivery technologies could provider greater benefits with a lower risk.
The VA would be required to preserve all of the data that it collects from the studies and issue a report to Congress within 180 days that includes a plan to implement the research. The VA would also have to send updates no less than annually for a period of five years.
What it Means
The new bill may not be a comprehensive bill legalizing medical cannabis research nationwide, but it’s a starting point that highlights growing bipartisan support for the movement.
Many cannabis advocates hope that the new research bill will go one step further and compel the VA to begin letting doctors issuing recommendations for military veterans in states where the drug has been legalized. By comparison, the current bill only supports the research of medical cannabis without guaranteeing that it will ever be prescribed.
Cannabis advocates and other industry participants will be keeping a close eye on these developments over the coming months as Congressional support for cannabis legalization appears to be on the rise.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.